- Home
- AACG vs CMMB Comparison
AACG vs CMMB Comparison
Compare AACG & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AACG | CMMB |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.9M | 13.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AACG | CMMB |
|---|---|---|
| Price | $0.79 | $1.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | 16.7K | ★ 105.9K |
| Earning Date | 11-12-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,316,403.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.62 | N/A |
| 52 Week Low | $0.71 | $1.60 |
| 52 Week High | $2.58 | $9.84 |
Technical Indicators
Market Signals| Indicator | AACG | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 34.94 | 23.07 |
| Support Level | $0.74 | $1.73 |
| Resistance Level | $0.85 | $2.24 |
| Average True Range (ATR) | 0.07 | 0.26 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 23.38 | 4.62 |
Price Performance
Historical ComparisonAbout AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.